Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)

Next Previous
Trial Profile

A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tezepelumab in Japanese Adults and Adolescents With Inadequately Controlled Severe Asthma (NOZOMI)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Acronyms NOZOMI
  • Sponsors AstraZeneca

Most Recent Events

  • 01 Mar 2023 Results assessing the long-term safety of tezepelumab in Japanese patients with severe uncontrolled asthma published in the Journal of Asthma
  • 27 Sep 2022 According to an AstraZeneca media release, results from the trial were published in The Journal of Asthma in June 2022.
  • 17 Jun 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top